Abivax SA Sponsored ADR $ABVX Position Lifted by Aberdeen Group plc

Key Points

• Aberdeen Group increased its Abivax stake by 45.8% in the third quarter, adding 238,991 shares to hold 761,016 shares, worth about $75.4 million. Institutional investors collectively own 47.91% of the company.
• Abivax shares fell 2.9% to $87.58 on Friday. The company reported a quarterly loss of $1.71 per share, wider than analysts’ $0.92 loss estimate, though revenue of $1.37 million exceeded expectations.
• Analyst sentiment is mixed but leans positive: MarketBeat reports a “Moderate Buy” consensus and a $155 average price target, while some firms maintain sell ratings.

Aberdeen Group plc grew its position in Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) by 45.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 761,016 shares of the company's stock after acquiring an additional 238,991 shares during the quarter. Aberdeen Group plc owned about 0.87% of Abivax worth $75,356,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Versant Capital Management Inc bought a new position in Abivax during the 2nd quarter valued at about $30,000. Assetmark Inc. grew its stake in shares of Abivax by 41.5% during the first quarter. Assetmark Inc. now owns 886 shares of the company's stock valued at $99,000 after buying an additional 260 shares during the last quarter. Troluce Capital Advisors LLC bought a new position in shares of Abivax during the second quarter valued at approximately $133,000. Engineers Gate Manager LP purchased a new stake in shares of Abivax in the second quarter worth approximately $284,000. Finally, Goldstein Advisors LLC raised its holdings in shares of Abivax by 49.6% in the third quarter. Goldstein Advisors LLC now owns 2,390 shares of the company's stock worth $237,000 after buying an additional 792 shares during the period. Institutional investors own 47.91% of the company's stock.

Abivax Trading Down 2.9%

Shares of Abivax stock traded down $2.62 on Friday, hitting $87.58. 698,793 shares of the company traded hands, compared to its average volume of 853,150. The stock's 50 day moving average price is $94.85 and its 200-day moving average price is $112.53. Abivax SA Sponsored ADR has a 52 week low of $69.81 and a 52 week high of $148.83. The company has a market cap of $7.67 billion, a PE ratio of -14.45 and a beta of 1.36.

Abivax (NASDAQ:ABVX - Get Free Report) last announced its quarterly earnings data on Monday, September 21st. The company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.79). The company had revenue of $1.37 million during the quarter, compared to the consensus estimate of $0.80 million. As a group, research analysts anticipate that Abivax SA Sponsored ADR will post -4.14 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on ABVX. Truist Financial decreased their price target on Abivax from $155.00 to $151.00 and set a "buy" rating for the company in a research note on Tuesday, September 22nd. Wall Street Zen downgraded Abivax from a "hold" rating to a "sell" rating in a research report on Saturday, September 26th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Abivax in a research report on Thursday, October 15th. The Goldman Sachs Group started coverage on Abivax in a research note on Wednesday, September 9th. They issued a "buy" rating and a $155.00 target price on the stock. Finally, Barclays reiterated an "overweight" rating and set a $148.00 target price on shares of Abivax in a research report on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $155.00.

Abivax Profile

Abivax is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body's immune response. The company's lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation. Founded in 2013, Abivax conducts clinical development internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.